Dermata Therapeutics通过私募资金筹集了410万美元，用于痤疮产品的发布和研究。 Dermata Therapeutics raised $4.1 million in a private placement to fund acne product launch and research.

Dermata Therapeutics（DRMA）宣布私募资金，最高筹集1240万美元，其中410万美元为预付款，若行使认股权证，可能获得额外资金。 Dermata Therapeutics (DRMA) announced a private placement to raise up to $12.4 million, with $4.1 million in upfront proceeds and potential additional funds if warrants are exercised. 该公司出售了2 022 062个股份或预先供资的授权令,每股2.04美元,连同C系列和D系列授权令,定于2025年12月29日左右关闭。 The company sold 2,022,062 shares or pre-funded warrants at $2.04 per share, along with Series C and D warrants, set to close around December 29, 2025. 收益将为公司活动提供资金,包括消费者研究、OTC Acne套件的启动和技术投资。 Proceeds will fund corporate activities including consumer research, launching an OTC acne kit, and technology investments. 内部人士以同样的条件参与。 Insiders are participating on the same terms. 现有逮捕证的实际执行价格从每股12.70美元减至2.04美元。 Existing warrants’ exercise price was reduced from $12.70 to $2.04 per share.